SAB Biotherapeutics, Inc. (NASDAQ:SABS) Stock Now Rated “Moderate Buy” by Sell-Side Brokerages

SAB Biotherapeutics, Inc. (NASDAQ:SABS) has been given a consensus recommendation of “Moderate Buy” by the eleven analysts that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $12.00.

SABS has been the topic of several analyst reports. Wall Street Zen upgraded SAB Biotherapeutics from a “strong sell” rating to a “sell” rating in a report on Monday, August 10th. Leerink Partners increased their price target on shares of SAB Biotherapeutics from $7.00 to $12.00 and gave the company an “outperform” rating in a research report on Monday, June 15th. Chardan Capital raised their price target on shares of SAB Biotherapeutics from $14.00 to $16.00 and gave the stock a “buy” rating in a report on Wednesday, June 17th. Barclays assumed coverage on SAB Biotherapeutics in a research note on Wednesday, June 24th. They issued an “overweight” rating and a $13.00 target price on the stock. Finally, Weiss Ratings raised SAB Biotherapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, September 17th.

Institutional Investors Weigh In On SAB Biotherapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. IFP Advisors Inc bought a new stake in SAB Biotherapeutics during the second quarter worth about $151,000. Seven Fleet Capital Management LP increased its holdings in shares of SAB Biotherapeutics by 47.2% during the second quarter. Seven Fleet Capital Management LP now owns 736,077 shares of the company’s stock valued at $2,871,000 after acquiring an additional 236,077 shares in the last quarter. AWM Investment Company Inc. purchased a new position in shares of SAB Biotherapeutics in the 2nd quarter worth about $1,462,000. Bank of New York Mellon Corp purchased a new position in SAB Biotherapeutics in the second quarter worth about $421,000. Finally, DV Trading LLC bought a new position in shares of SAB Biotherapeutics in the first quarter worth approximately $1,532,000. 7.82% of the stock is owned by hedge funds and other institutional investors.

SAB Biotherapeutics Price Performance

Shares of SAB Biotherapeutics stock opened at $2.93 on Wednesday. The firm has a market capitalization of $266.59 million, a PE ratio of -2.25 and a beta of 0.58. The company has a current ratio of 9.22, a quick ratio of 9.22 and a debt-to-equity ratio of 0.01. SAB Biotherapeutics has a 12 month low of $2.10 and a 12 month high of $5.15. The business’s 50-day moving average price is $3.57 and its 200-day moving average price is $3.68.

SAB Biotherapeutics (NASDAQ:SABS) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.28) EPS for the quarter, meeting analysts’ consensus estimates of ($0.28). Sell-side analysts forecast that SAB Biotherapeutics will post -1.17 EPS for the current fiscal year.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines for infectious diseases, immune disorders and other serious health conditions. The company’s approach is designed to produce fully human polyclonal antibodies that can recognize and neutralize multiple targets associated with a disease.

SAB’s technology platform, known as DiversitAb, uses genetically engineered cattle with human immune-system components to generate human antibodies.